Press Releases

Oculus Innovative Sciences Provides 2010 U.S. Milestones Update Dec 3, 2009 08:08AM

Microcyn(R)-Based Product Introductions:

    --  Orthopedic and Surgical - Microcyn Technology Product Introduction into
        Orthopedic and Surgical Markets (Jan. 2010)
    --  Negative-Pressure Wound Therapy - Microcyn Technology Product
        Introduction as Accessory for Negative-Pressure Wound Therapy Devices
        (Feb. 2010)
    --  Microcyn Skin and Wound HydroGel - Dermatology Indications - Microcyn
        Technology HydroGel Product Introduction into Dermatology Market (Q2
        2010)

Microcyn-Based Products FDA Clearances:

    --  Upper Respiratory - Expecting FDA Clearance for Allergy Block HydroGel
        (Q3 2010)
    --  Second Dermatology Product - Expecting FDA Clearance for Atopic
        Dermatitis HydroGel (Q3 2010)

Oculus Partner Updates:

    --  Animal Health - Vetericyn(TM) Animal Products Introduced into Canine
        Market through Dog Whisperer, Cesar Millan (Current)
    --  Professional Oral Care - Microcyn Technology Products FDA Cleared and
        Introduced into Oral Biofilm and Mucoprotectant Market (Q2/Q3 2010)

PETALUMA, Calif.--(BUSINESS WIRE)-- Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, initially intended to treat chronic and acute wounds, today unveiled an expanded regulatory/commercial pipeline for its Microcyn-based products as preparation for the company's CEO and founder, Hoji Alimi, to provide even greater detail at the OneMedForum on January 12, 2010 in San Francisco.

"We see 2010 as being a breakout year in terms of U.S. product regulatory clearances, new product introductions, revenue growth and partner activities. While we're unable to control the timing of the FDA review process, we believe these anticipated marketing clearances will be transformative, creating added revenue streams that will help get us to revenues of greater than $45 million to $60 million with operating profitability of 20% by 2013," said Hoji Alimi, Oculus CEO and founder. "Based upon shareholder feedback, we have decided to provide greater transparency in terms of identifying the 2010 milestones by which we will measure our success over the coming year. I think it important that investors be able to see the extensive efforts being put forth by Oculus' R&D and marketing teams, as well as our U.S. partners, to move beyond the existing product portfolio and generate new Microcyn-based products for applications including orthopedic and surgical irrigation, an advanced solution that is complementary to negative-pressure wound therapy devices, oral care, dermatology treatments and allergy relief."

United States Product Introductions:

Orthopedic and Surgical Irrigation - (Introduction: Jan. 2010)

Packaged in a sterile, spikeable bottle that is ideal for use in orthopedic and surgical applications, Oculus will introduce Microcyn OSID in January of 2010. Oculus will leverage its 30-second kill times in solution against dangerous pathogens such as MRSA and VRE. Unlike current standards of care, Microcyn OSID is non-foaming, non-sensitizing, and based upon evidence, does not appear to facilitate resistant strains of bacteria.

Adam Landsman, DPM, Ph.D. and assistant professor of surgery at Harvard Medical School in Boston, who was lead investigator in a Phase II trial in which the Microcyn Technology was used to treat mildly infected diabetic foot ulcers in 2007, stated: "The current standard for surgical wound cleansing and irrigation involves the use of products that do not kill the MRSA infection in-vitro. This is important in light of the skyrocketing proliferation of these dangerous bacteria as well as the evolving 'super bug' mutations. Microcyn is also highly attractive since it does not produce foam, which hampers visualization of the wound. And finally, with the health community so vitally focused on cost savings, the Microcyn OSID will actually cost less than the current combination of saline and bacitracin."

For years, the standard of care for surgical irrigation was saline infused with bacitracin, an antibiotic first discovered in 1945. According to the journal Orthopedics (2008; 31:37), due to resulting resistance, bacitracin is no longer considered effective for MRSA decolonization. Surgical irrigation and debridement remains the standard of care for removal of necrotic tissue and is used when the tissue removal needs are extensive, or when the patient has a serious infection associated with the surgical wound site.

According to Medtech Insight, a Division of Windhover Information, in 2004 there were approximately 36 million surgical wounds and nine million open trauma wounds in the United States. Initially, Microcyn OSID(TM) will be marketed by the Advocos sales team that is currently selling the professional formulations of the Microcyn-based wound care products.

Accessory for Negative-Pressure Wound Therapy (NPWT) Devices - (Introduction: Jan. 2010)

According to U.S. Markets for Current and Emerging Wound Closure Technologies, a report published in April 2009 by Medtech Insight, 2009 sales of negative-pressure wound therapy products will total approximately $1.1 billion. Oculus' new Microcyn NPWT solution can be used in conjunction with the NPWT devices from Kinetic Concepts Inc., Smith and Nephew, ConvaTec, Innovative Therapies, Medela, NovaSpine and Boehringer Wound Systems.

Microcyn Skin and Wound HydroGel - Dermatology Indications - (FDA Regulatory Clearance and Introduction: Q2 2010)

Oculus has filed a 510(k) application with the FDA to secure marketing clearances of the Microcyn HydroGel product for dermatological uses. This clearance is expected in the first half of 2010. The indication under review proposes that the HydroGel, under the supervision of a medical professional, be used for treatment of first- and second-degree burns (including sunburns), radiation dermatitis, itching, skin conditions associated with periostomy care, skin irritation associated with tattooing procedures, irritation and pain following skin laser resurfacing treatment, dermabrasion therapy and chemical peels.

United States Regulatory Clearances:

Allergy Block HydroGel OTC - (FDA Regulatory Clearance: Q3 2010)

Microcyn Allergy Block HydroGel(TM) is designed as a self-contained package of disposable applicators and an anti-allergy formulation of Microcyn HydroGel to be applied to the interior of the nasal cavities for relief from allergy symptoms including allergic rhinitis.

An allergy is an overreaction of the immune system to a substance that's harmless to most people. But in someone with an allergy, the body's immune system treats the substance (called an allergen) as an invader and reacts inappropriately, resulting in symptoms that can be anywhere from annoying to possibly harmful to the person. In an attempt to protect the body, the immune system of the allergic person produces antibodies called immunoglobulin E (IgE). Those antibodies then cause mast cells to release chemicals, including histamine, into the bloodstream to defend against the allergen.

There were more than 12 million physician office visits because of allergic rhinitis in 2006, affecting between 10% and 30% of all adults and as many as 40% of children. From 2000 to 2005, the cost of treating allergic rhinitis almost doubled from $6.1 billion (in 2005 dollars) to $11.2 billion. More than half of that was spent on prescription medications.

Atopic Dermatitis HydroGel Rx - (FDA Regulatory Clearance: Q3 2010)

An FDA clearance for a prescription Microcyn AD HydroGel(TM) specially formulated for the treatment of atopic dermatitis is expected in Q3 2010, after which time it will be marketed to the nearly 16,000 U.S. dermatologists.

Atopic dermatitis is a common and chronic inflammatory skin disease marked by red, itchy rashes. It has been increasing in prevalence over the past two decades and affects a disproportionate number of children. According to current estimates, approximately 15 percent to 20 percent of children in the United States and other industrialized countries around the world develop atopic dermatitis in the first few years of life. By comparison, only an estimated three percent to five percent of adults have an active form of the condition.

The skin of a patient with atopic dermatitis reacts abnormally and easily to irritants, food, and environmental allergens and becomes red, flaky and very itchy. It also becomes vulnerable to surface infections caused by bacteria. The skin on the flexural surfaces of the joints (for example inner sides of elbows and knees) are the most commonly affected regions in people. Although there is no cure for atopic eczema, and its cause is not well understood, it can be treated in the short term through a combination of prevention (learning what triggers the allergic reactions) and drug therapy.

According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, in a recent analysis of the costs associated with atopic dermatitis in the United States, researchers reviewed studies evaluating both direct costs (doctor visits, hospitalizations, and medicine) and indirect costs (over-the-counter remedies, lubricants, and days lost from work). They found that direct costs totaled about 25 percent, and indirect costs totaled about 75 percent of costs. Per patient, the costs averaged about $600 per year. On the whole, direct costs alone may exceed $3 billion per year.

Oculus Partner Updates:

Vetericyn(TM) Animal Healthcare Products - (Current)

Following the successful introduction via a national advertising campaign of the Vetericyn products into the equine market by Oculus' partner, Innovacyn, Vetericyn products for the canine market are now being promoted via the world-famous Cesar Millan and his Dog Whisperer(R) franchise.

Oral Antibiofilm and Mucoprotectant - (FDA Regulatory Clearance and Introduction: Q2/Q3 2010)

As announced in July 2009, Oculus licensed the Microcyn Technology to OroScience, Inc. for the professional oral care markets in the United States, Canada and Europe. OroScience anticipates initially introducing two Microcyn-based products, namely Periocyn(TM) Antitbiofilm Rinse for the treatment of gingivitis and Periocyn(TM) Mucoprotectant for the treatment of oral mucositis. OroScience believes FDA clearances to market these products are expected by early second quarter 2010.

Gingivitis is an inflammation of the gingival (gums) characterized by a change in color from normal pink to red, with swelling, bleeding, and often sensitivity and tenderness. Gingivitis is caused by bacteria in the biofilm or dental plaque that forms on oral surfaces. If left untreated, gingivitis can progress to more severe forms of periodontal disease and result in deep pockets between the teeth and gums and loss of bone around teeth and eventual loss of teeth as well as halitosis (bad breath). In a 1999 study reported by the Centers for Disease Control and Prevention, 50.3% of the U.S. population aged 30 years or older were afflicted with gingivitis. Early and sustained treatment of gingivitis is an important factor in preventing the progression of gingivitis to more severe forms of periodontal disease.

Oral mucositis (OM) is a common, painful, and often debilitating side effect of cancer therapy such as chemotherapy and radiotherapy. OM is estimated to affect more than 800,000 cancer patients each year in the EU and United States. OM affects approximately 40% of cancer patients who receive chemotherapy, more than 70% of those undergoing conditioning therapy for bone marrow transplantation, and patients receiving radiation therapy for head and neck cancer. The economic impact of mucositis can be significant, as the need for prolonged hospital stays, nutritional therapy and treatments for pain and infection can drive up the costs of therapy.

These professional Microcyn-based oral care products, along with future applications, will be distributed by OroScience beginning in mid-2010 via a large global dental distributor. Oculus retains the right to either market or license the over-the-counter formulations globally.

OneMedForum 2010 Update:

Hoji Alimi, Oculus CEO and founder, will provide a regulatory and commercialization update relative to the U.S. pipeline as well as advances being realized in the international markets during his 10:45 am, January 12, 2010 OneMedForum presentation at the Sir Francis Drake Hotel in San Francisco.

About Oculus Innovative Sciences

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which includes new formulations designed to significantly reduce the need for antibiotics as it reduces infections. The Microcyn Technology platform features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries under various country specific regulatory clearances and approvals. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increase blood flow to the wound site, reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with operations in Latin America. More information can be found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company's commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as "introduced," "expecting," "will," and "generate," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2009. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.

Oculus Innovative Sciences, Microcyn, Dermacyn and Vetericyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

    Source: Oculus Innovative Sciences, Inc.

Cash for Gold USA Offers Tips on How to Make Money for the Holidays Dec 3, 2009 08:07AM

SHARON, Mass., Dec. 3 /PRNewswire/ -- Cash for Gold USA, the nation's top rated buyer of unwanted or broken gold jewelry, sterling silver and diamonds is now offering free tips on how customers can make quick, extra cash for their holiday needs.

Get a $25.00 Holiday Bonus

Cash for Gold USA is offering a $25.00 Cash Bonus to customers whose Gold, Silver and Diamonds are valued at $200 or more. With market prices so high, this could be achieved by sending in as little as a couple gold rings or a bracelet. This popular cash perk adds an additional $25.00 to the total payout received and should prove a welcome extra at this time of the year.

'Refer a Friend' Program - Making Money for Free

This service is available to everyone, not just their customers.

Simply visit http://cashforgoldusa.com, fill out the form and add your friends email addresses. Then, as soon as your referral comes in, they'll cut you a check for 10% of the value of each referral's property. Some of their customers who advertise the link on Facebook and MySpace are earning thousands of dollars every month.

Cash for Gold USA Guarantees the Highest Payouts

The higher the price of gold soars, the more new buyers pop up. And now that gold has topped $1,200/ounce, this will undoubtedly continue. Cash for Gold USA is committed to remaining the Internet's top source for the highest and fastest payouts along with bonuses and special offers that boost payouts even higher. Their prices will not be beaten.

According to Norman Schneider, president, "We know from experience that it pays to 'share the wealth' by giving our customers the very highest cash payouts for their gold, silver and diamonds. This is clearly evidenced by the large number of referrals we get from our 'Refer a Friend' program; the steady increase in the volume of business we do and the great reviews we get from the media and third party websites. We fully intend to keep this ball rolling through 2010--and beyond."

The Company Also Buys Silver, Diamonds and Platinum

Cash for Gold USA is a division of CJ Environmental, one of the nation's leading refiners of precious metals. The company also buys silver and diamonds through: http://cashforsilverusa.com and http://cashfordiamondsusa.com, respectively, where sellers obtain the same safety, reliability, high payouts and fast turnaround on the items they wish to sell.

Customers who sell their broken and unwanted gold jewelry to Cash for Gold USA can add an additional 10% to their earnings merely by referring friends and associates.

FOR MORE INFORMATION:
Mr. Sam Errama, Director of Public Relations
CashForGoldUSA
101 Hampton Road
Sharon, MA 02067
Tel: 1-888-GOLD-808
info@cashforgoldusa.com

SOURCE Cash for Gold USA

Telx Increases Power, Space in Downtown Atlanta Dec 3, 2009 08:05AM

NEW YORK, NY and ATLANTA, GA -- (MARKET WIRE) -- 12/03/09 -- Key Highlights:

-- New space offers high power density to better serve enterprise customers.

-- Provides low-latency connectivity to many media & entertainment firms, educational institutions, research organizations and cloud computing providers.

-- Enables higher-density storage and data sharing capabilities among all verticals.

Telx, one of the largest domestic interconnection and colocation data center operators, announced today that it has increased power capacities across 20,000 square-feet of conditioned data center space within its building at 56 Marietta Street in Atlanta. The newly re-configured SAS 70 certified space is designed to support up to 200 watts per square foot of IT load, and will meet or exceed the Uptime Institute's Tier III rating for data centers. Additionally, the scalable, flexible, mission-critical architecture allows for highly efficient power utilization within the space.

Telx's 56 Marietta St. facility has long been recognized within the industry as one of the most densely interconnected facilities in the Southeastern United States. The combination of enhanced power supplies and the most dense collection of networks in the Southeast offers enterprise customers powerful proximity networking capabilities and the necessary power to meet the most demanding computing, data storage and backup, and network connectivity needs.

"56 Marietta Street's roots are that of the pre-eminent carrier hotel in the Southeast and have long served the wide variety of prominent enterprise companies that call Atlanta home," said Michael Terlizzi, Executive Vice President of Operations for Telx. "The transition of this space from low-density, high-interconnection to high-density, high-interconnection adds tremendous value to our customers and is unparalleled in the colocation and interconnection marketplaces."

The addition of new space not only increases capabilities for enterprise customers, but for current Telx service providers that now offer connectivity and solutions within Telx's 56 Marietta Street facility.

"Telx's additional power allows Colocube to provide higher density managed service solutions to our customers," said Matt Elkourie, CTO of high-performance IT hosting and IP services provider Colocube. "The addition of this high-density power and added space will help us to meet and exceed our customers' needs, both now and in the future as technology continues to evolve."

Telx's new space, like all of 56 Marietta, offers industry-leading power and cooling systems to ensure optimal reliability and up-time for customers. The new space is available immediately and in addition to typical cabinet and cage configurations, can be leased as fully-conditioned or custom-built suites as well as powered shell space. For more information on leasing space in 56 Marietta, contact sales@telx.com.

About Telx

Telx is a world-class leader in providing interconnectivity solutions through their network-neutral and network rich, colocation facilities. With 15 facilities in North America, Telx offers cost effective networking solutions for customers to seamlessly access diverse global networks and exchange information in a secure and reliable environment. More than 700 leading telecommunications carriers, ISPs, content providers and enterprises rely on Telx's world-class team to support their mission-critical global infrastructure needs and to create a global connectivity marketplace to dramatically expand their business growth opportunities. Telx is a privately held company headquartered in New York City with four facilities in the New York Metro area, two facilities in Chicago, two facilities in Dallas, three facilities in California, (Los Angeles, San Francisco, Santa Clara) and facilities in Atlanta, Miami, Phoenix and Charlotte, N.C. For more information about Telx, visit www.telx.com.

About Colocube

Colocube is a US-based managed hosting firm specializing in high-performance Managed IT hosting, Data recovery storage and IP Transit Services with a global presence. Colocube is carrier-neutral and offers the richest connectivity and dedicated service options in the most secure and reliable facilities for our customers' mission critical operations. Colocube has rapidly become one of the most respected high performance hosting companies in the industry. Colocube has partnered with premier companies to provide best in class service to our customers. For more information about Colocube, visit www.colocube.com.

Contact:
Jennifer Sauer
Telx
+1 347 562 0218
Email Contact

Tandy Leather Factory, Inc. Reports November 2009 Sales Up 13% Over November 2008 Dec 3, 2009 08:05AM

Retail Up 20%; Wholesale Up 8%; International Up 53%

FORT WORTH, Texas--(BUSINESS WIRE)-- Tandy Leather Factory, Inc. (AMEX: TLF) reported today that sales for the month of November were $5.2 million, up 13% from November 2008 sales of $4.6 million. 2009 year to date sales total $49.5 million, a 2% increase over 2008 year to date sales of $48.5 million.

Retail Leathercraft's sales rose 20% to $2.7 million compared to November 2008 sales of $2.2 million. The 73 comparable stores' sales were up 18% for the month compared to the same period last year. The 2 stores opened since November 2008 added November sales of $56,000. Year-to-date sales for Retail Leathercraft are $24.9 million this year, a 10% increase over sales of $22.6 million for the same period of 2008. For the year to date, the 72 comparable stores' sales were up 8% compared to sales reported for the same period in 2008.

Wholesale Leathercraft posted sales of $2.3 million for November, up 8% from November 2008 sales of $2.2 million. Within the Wholesale Leathercraft division, the wholesale centers' sales were up 7% for the month while the National Account group's sales were up 13% against November 2008. For the year to date, Wholesale Leathercraft sales are $22.8 million compared to $24.4 million in 2008, down 6%.

International Leathercraft, which consists of one store in the UK, reported November sales of $127,000, a 53% increase over sales of $83,000 in November 2008. For the year to date, 2009 sales for International Leathercraft totaled $1.2 million, a 59% increase over 2008 sales of $753,000. The UK store opened in February 2008 as a combination retail and wholesale store.

Chief Executive Officer and President, Jon Thompson, commented, "Our wholesale stores broke their nineteen-month consecutive streak of sales declines. And our Retail and International Leathercraft divisions continue their very positive sales trends. With the sales momentum generated in October and November, I fully expect we will have a fourth quarter sales gain. Sales gains of any size in this environment are considered positive."

Shannon Greene, Chief Financial Officer and Treasurer, added, "Some good things are happening at our wholesale stores, but it is too early to tell if we have 'turned the corner' in that division. Regardless, I am proud of the efforts of our wholesale store managers and glad to have good news to report there. Cash continues to accumulate, and our inventory is in good shape to finish the year. I think it is safe to say we will beat our 2008 sales and earnings."

Tandy Leather Factory, Inc., (http://www.tandyleatherfactory.com), headquartered in Fort Worth, Texas, is a specialty retailer and wholesale distributor of a broad product line including leather, leatherworking tools, buckles and adornments for belts, leather dyes and finishes, saddle and tack hardware, and do-it-yourself kits. The Company distributes its products through its 29 Leather Factory stores, located in 19 states and 3 Canadian provinces, 75 Tandy Leather retail stores, located in 36 states and 5 Canadian provinces, one combination wholesale/retail store located in the United Kingdom, and Mid-Continent Leather Sales, one store located in Oklahoma. Its common stock trades on the NYSE Amex with the symbol "TLF". To be included on Tandy Leather Factory's email distribution list, go to http://www.b2i.us/irpass.asp?BzID=1625&to=ea&s=0.

This news release may contain statements regarding future events, occurrences, circumstances, activities, performance, outcomes and results that are considered "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Actual results and events may differ from those projected as a result of certain risks and uncertainties. These risks and uncertainties include but are not limited to: changes in general economic conditions, negative trends in general consumer-spending levels, failure to realize the anticipated benefits of opening retail stores; availability of hides and leathers and resultant price fluctuations; change in customer preferences for our product, and other factors disclosed in our filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and except as required by law, we do not intend to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    Source: Tandy Leather Factory, Inc.

LL Cool J's New 'Best of' Album, All World 2, Features Never-Before-Compiled Hits, Favorites and Rarities Dec 3, 2009 08:05AM

LOS ANGELES, Dec. 3 /PRNewswire/ -- LL Cool J - the first rap teen idol, first rapper with four consecutive albums, first to earn four gold singles, first to hit No. 1 R&B, first to headline "MTV Unplugged;" a multi-talented performer, actor (currently starring in the new TV series "NCIS: Los Angeles") and entrepreneur - opened the doors for rap's mass popularity. Today, during Def Jam Recordings' 25th anniversary, he remains the exceptional hip-hop star who has flourished for that entire run - demonstrated by a new "best of" collection, All World 2 (Def Jam/UMe), to be released December 8, 2009. This new set not only fills in the gaps from 1996's platinum All World: Greatest Hits but updates LL's career with hits and favorite tracks released since then, while reprising a few cuts from his immensely successful career.

Six of the 17 recordings on All World 2 hit the Top 40 Pop chart; 12 were Top 40 Rap (including eight Top 10s). The compilation reaches back to his 1985 debut album, Radio, for "Rock The Bells" (Top 20 R&B, before there even was a Rap chart) and "Dear Yvette," and to his third album, 1989's platinum Walking With A Panther, to retrieve the gold No. 1 Rap "I'm That Type Of Guy" (also Top 40 Pop/Top 10 R&B) and the Top 20 Rap "Big Ole Butt." Following are the No. 1 Rap "Around The Way Girl" (also Top 10 Pop/Top 5 R&B), Top 20 Rap and R&B "To Da Break Of Dawn" and "Jack The Ripper" from the double platinum Mama Said Knock You Out (1990); the No. 2 Rap hit "Pink Cookies In A Plastic Bag Getting Crushed By Buildings" from the gold 14 Shots To The Dome (1993) and the "I Shot Ya (Remix)" featuring Fat Joe, Foxy Brown and Prodigy spun off from the double platinum Mr. Smith (1995).

Picking up where All World: Greatest Hits left off, All World 2 mines 1997's gold Phenomenon for its Top 10 Rap "4, 3, 2, 1," the video version featuring Method Man, Redman and DMX; and the album's title track. Culled from 2000's aptly-titled gold G.O.A.T. Featuring James T. Smith: The Greatest Of All Time is the Funkmaster Flex track featuring LL, "Ill Bomb," and from 2002's gold 10 are the No. 2 Rap, Neptunes-produced "Luv U Better" (also No. 4 Pop/No. 1 R&B) and Top 10 Rap "Paradise" (also Top 40 Pop). The gold, Top 10 Rap, Timbaland-produced "Headsprung" (also Top 40 Pop) and Top 40 Pop/Top 20 Rap "Hush" are from the gold 2004 The DEFinition. All World 2 also includes the Top 10 Rap "Baby" featuring The-Dream from 2008's Exit - LL's final album for Def Jam, for which the then-16-year-old recorded the label's first single back in the day.

Combined, All World: Greatest Hits and All World 2 tell the complete musical story of one of rap's first great stars.

www.ilovethatsong.com

SOURCE Universal Music Enterprises